- Inhibition of Autophagy Suppresses Intrinsic Resistance of Her2+ BC to therapies
- Adjuvant Trastuzumab Effect on HER2+ Breast Cancers According to Hormonal Status
- HER-2 Testing and Treatment – Is Age a Factor?
- Sexual Dysfunction in Premenopausal Women with Breast Cancer: Prevalence and Severity
- Sexual Dysfunction in Women with Early Stage Breast Cancer on Endocrine Therapy
- Cognitive Function and Reproductive Hormones in Women Receiving Anastrozole
- NSAID Analgesic Ketorolac Used Perioperatively May Suppress Early BC Relapse
- Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2+ BC
- Acquired Tamoxifen Resistance Promotes Angiogenic Responses in ER+ BC Cells
- Genomic Instability in Breast Cancers from Atomic Bomb Survivors
- Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ BC
- Correlation between Quantitative HER2 Protein Expression and Risk of Brain Metastases
- Pooled Analysis of Outcomes of T1a/bN0, HER2-Amplified Breast Cancer
- Prognostic Value of HER2+/ER- in small NN tumors
- Influence of Delayed Zoledronic Acid on DFS in post-meno, HR+ BC
- Relationship of meno symptoms & arthralgia to OS in endocrine therapy
- Systemic Adjuvant Treatment of T1a and T1b N0M0 HER2+ Breast Carcinomas
- Making the Case for Fucose-Depleted Trastuzumab
- Macrophages as Novel Targets for Therapy in Breast Cancer
- Tumor Heterogeneity and Metastasis
- Patterns of Distant Metastasis According to the Molecular Subtypes
- Increased cellular expression activity of minimal residual disease in bc post-surgery
- Are Single Node Metastases More Common in Patients with Breast Cancer in the SNB Era?
- Change in Carbohydrate Intake and Breast Cancer Prognosis
- Intermittent Dietary Carbohydrate Restriction Enables Weight Loss
- Metformin for Breast Cancer Prevention: A Pilot Study
- PR- Predicts Poor Outcome in ER+ NN BC
- Influence of the Progesterone Receptor on Prognosis
- Systemic Cholesterol promotes Breast Tumor Aggressiveness
- CA15-3 Adds Prognostic Information in “Luminal” Type Breast Cancer
- Thyroid Disease Is Associated with Breast Cancer: A Meta-Analysis
- Risk Factors for Relative Weight Gain >10% in Breast Cancer Survivors
- Trastuzumab Does Not Increase the Incidence of CNS Relapses in HER2+ EBC
- Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ MBC
- Brain Metastasis Free Survival (BMFS) Differs between Breast Cancer Subtypes
- The Shifting Landscape of Metastatic Breast Cancer to the CNS
- Is Cranial MRI Necessary for Staging of Asymptomatic HER2+ BC Patients?
- Extrinsic and Intrinsic Force Regulation of Breast Cancer Progression and Treatment
- HIF-1, Metabolism, and Breast Cancer Metastasis
- Translational Science Insights Relevant to Effects of Diet, Exercise, and Metformin
- Preoperative Endocrine Therapy: New Approaches
- Mammographic Microcalcifications and Breast Cancer Tumorigenesis
- Stage IV at Presentation – Are HER2 Positive Tumors Overrepresented?
- Patients' Views about How Oncologists Should Explain Prognosis in Advanced Cancer
- A Population Level Assessment of Emergency Room Visits and Hospitalizations for chemo
- Survival in Women with Breast Cancer Who Used or Did Not Use Scalp Cooling
- Multicenter Results of Scalp Cooling To Prevent Chemotherapy-Induced Alopecia
- The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV BC
- 13-gene signature to predict rapid development of brain mets in advanced Her2+ bc
- Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS)
- Impact of adjuvant trastuzumab on outcomes of HER2+ mbc
- Impact of hormone receptor status on patterns of recurrence in Her2+ bc
- Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2+ bc
- Quantitative HER2 levels and steroid receptor expression in primary bc and brain mets
- Incidence and risk of brain mets as site of first recurrence after adj Herceptin
- Long-term follow-up of patients with durable complete response after chemo/H for mbc
- Estrogen receptor in HER2-positive early breast cancer: Two different diseases?
- Impact of exogenous female hormone use on BC recurrence as assessed by Oncoty
- Prognostic factor Ki67 for breast cancer patients in each subgroup
- The role of Ki-67 in molecular breast cancer classification
- Correlation between weight at diagnosis, weight gain after breast cancer & recurrence
- Does obesity change the effect of AIs on estradiol, leptin, insulin, and IGF-1 serum
- Variations of the ER, PR, and HER2 expression status according to operation day
- The effect of cholesterol depletion in resistant breast cancer cells
- Statin use decreased bone mets
- Non-breast solid malignancies among breast cancer survivors
- Significance of chromosome 17 polysomy in breast cancer
- Changes in glucose, insulin, and insulin resistance from presurgery to post adjuvant
- Relationship between cancer and allergy
- Low-dose, short-course sunitinib may normalize tumor vasculature & improve chemo effi
- Efficacy of low-dose capecitabine in metastatic breast cancer
- Prognostic impact of weight change during chemotherapy
- Incidence and implications of oligometastatic breast cancer
- Safety and long-term maintenance of anti-HER2 immunity following booster inoculations
- Response of HER2+ breast cancer patients to allogeneic cell immunotherapy
- Comparison of primary care providers’ and oncologists’ preferences for survivor care
- Oncologists' and primary care providers' awareness of late effects of cancer treatmen
- The use of the word “cure” in oncology
- Sexual functioning in young women with breast cancer
- Low-level laser therapy for chemotherapy-induced peripheral neuropathy
- Coping with the burden of taste alteration, a toxicity of taxane-based chemotherapy
- Association of core needle biopsies with increase in metastatic dissemination of bc
- Prediction of late metastasis in node-negative breast cancer
- Molecular Profiling Doesn't Trump Standard Pathology
- Link to the 2012 SABCS Abstract book
- P5-16-02 Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vac
- P5-16-05 The combination of trastuzumab and HER2-directed peptide vaccines is safe in
- Vaccine significantly reduces relapse in Her2+ and Her2-
- Paget's Information from SABCS abstract
- Determing support for the stigma of MBC
- low dose estradiol for AI resistance
- Her2 therapy for Her2 "negative"?
- Modeling Cancer Recurrence and the Therapeutic Effect of Adjuvant Systemic Therapy
- Estrogen Receptor Positivity: 10% or 1%?
- Effects of Chemotherapy on the Ovary: What You Didn't Know
- Weight Change and Risk of Incident Diabetes after Breast Cancer
- Limited Absorption of Low Dose 10µg Intravaginal 17-β Estradiol (Vagifem®)
- Ultra-Low Dose Vaginal Estriol and Lactobacillus Acidophilus (Gynoflor®)
- Efficacy and Safety of Scalp Cooling (SC) Treatment for Alopecia Prevention
- Impact of Body Mass Index (BMI) on the Efficacy of Aromatase Inhibitors
- Survival Impact of Early Detection of Recurrence after Surgery in Early Breast Cancer
- Novel Insight into the Tumor “flare” Phenomenon and Lapatinib Resistance
- Diabetes Increases the Risk of Breast Cancer
- Hormone Replacement Therapy, Is There an Increased Risk of In Situ Breast Cancer?
- The Effect of Weight Change on Breast Adipose and Dense Tissue
- Selective Crossover in Randomized Trials of Adjuvant Trastuzumab
- Identification of ErbB2 Function in the Heart
- Vitamin D Induces Expression of Estrogen Receptor and Restores Endocrine Therapy Resp
- Estradiol Levels in Postmenopausal ER+/PR+ > Than in Postmenopausal ER+/PR- BC
- Leptin and Leptin Receptor Expression in Human Breast Cancer
- Prognosis of Metastatic Breast Cancer Subtypes: ER+/HER2+ Is Associated with the Most
- Disease-Related Outcomes with Adjuvant Chemotherapy in HER2+ or TN small tumors
- Inhibition of mTOR and FASN Overcome Acquired Resistance to Traztuzumab
- The Effect of HER2 Expression on Luminal A Breast Tumors
- Effect of Metformin on Apoptosis in a Presurgical Trial in Non-Diabetic BC Patients
- Whole-Genome Progression of Breast Cancer from Early Neoplasia to Invasive Carcinoma
- Patients Carrying CYP2C8*3 Are at Increased Risk of Paclitaxel-Induced Neuropathy
- Extended adjuvant tamoxifen for early breast cancer: A meta-analysis
- CYP2D6 phenotype and Tamoxifen dosing
- Periodontal health in early-stage postmenopausal breast cancer survivors on AIs
- Comparative analysis of bone marrow micrometastases with sentinel lymph node status
- Relationship of tumor and stromal autophagy and endocrine responsiveness in bc
- Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC?
- A study on the prevalence of HER2 genetic heterogeneity and its impact on bc survival
- ER as a predictor of early breast cancer (EBC) outcomes in patients
- Prediction of early and late distant recurrence in early-stage breast cancer with BC
- Evaluation of factors related to late recurrence (later than 10 years after bc dx)
- Long-term survival of women with breast cancer with ≥10 lymph nodes at diagnosis
- Demographic and clinicopathologic characteristics in patients with invasive bc
- Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA tria
- The prognostic role of androgen receptor in early-stage breast cancer patients
- When less is better: Safety and efficacy of combination of trastuzumab and metronomic
- HER2-positive disseminated tumor cells in bone marrow of patients with HER2- tumors
- Brain and tumor penetration of carbon-11–labeled lapatinib ([11C]Lap)
- Prognostic value of HER2 on breast cancer survival
- A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor
- Impact of delaying initiation of adjuvant chemotherapy in breast cancer patients
- Does radiation therapy increase late cardiac death in patients with left bc?
- Distinctive lipid profiles of human breast cancer and adjacent normal tissues
- Outcomes of HER2-positive nonmetastatic breast cancer patients w/wo BRCA mutations
- Breast cancer mortality among users of cholesterol-lowering drugs
- Chemoprevention of cancer with metformin: A meta-analysis
- The relationship between serum vitamin D levels and breast cancer prognosis
- The role of chemotherapy in ER+ and HER2+ breast cancer patients over age 70
- Antibiotic exposure and risk of breast cancer: A causal association or a skyfall?
- Effect of dormant cancer cells on angiogenesis after resisting chemotherapy
- Patient perceptions about potential side effects and benefits from chemotherapy agent
- Continuing to work while receiving cancer treatment: A financial or a symbolic issue?
- Arrhythmias during and after zoledronic acid infusion patients with bone metastasis
- Taking control of cancer: Why women are choosing mastectomy
- Perceived versus measured functional vaginal capacity in cancer patients
- Actigraphy measured sleep disruption as a predictor of survival in advanced bc
- Nonalcoholic fatty liver disease after adjuvant therapy in nonmetastatic breast cance
- Discussions regarding reproductive and sexual health among young adult survivors
- Bridging to survivorship in breast cancer: How BMI weighs in
- Use of intravaginal 17-β estradiol to improve sexual function in AI patients
- Long-term quality of life of breast cancer survivors
- Efficacy of scalp cryotherapy in preventing alopecia among patients with breast cance
- Skin care tips during radiation - from the Mayo Clinic
- PIK3CA mutations and/or low PTEN predict resistance to combined Herceptin/Tykerb
- NSAID use attenuates breast cancer recurrence in obese women
- The therapeutic sensitivity of ER+/Her2+ breast cancer cells is attenuated in 3D matr
- Risk of recurrence following 5 years of adjuvant hormone therapy for hr+ ebc
- Comparison of cardiovascular outcomes in postmeno women treated w/AI's vs. Tamoxifen
- Intermittent letrozole as adjuvant treatment in postmenopausal hr+ bc
- Whole genome methylation patterns in male and female breast cancer – Unexpected findi
- Mammographic microcalcifications and breast cancer tumorigenesis
- Resveratrol blocks the protumorigenic effects of obesity in a postmenopausal bc
- Chronic inflammation and the development of breast cancer
- Identification of synergistic drug combination for HER2 positive breast cancer
- The clinicopathological features of androgen receptor expression in primary HER2+ bc
- Clues to the metabolic fingerprint of inflammatory breast cancer
- HER2 copy number on FISH as a predictor of disease severity in HER2- breast cancer
- Association between metformin use and improved survival in breast cancer patients
- HER2/HR positive early breast cancer patients have the highest disease-free survival
- Impact of estrogen receptor (ER) and HER2 co-expression on breast cancer characterist
- Permanent chemotherapy induced alopecia in early breast cancer patients
- Cutaneous toxicity and recovery: Is there a difference between breast cancer patients
- Redefining the breast tumor margin through genomics of the tumor-stromal interaction
- Seasonal variation in onset of inflammatory breast cancer: Evidence of an infectious
- The Will Rogers phenomenon in breast cancer
- Sexual function, sexual activity and quality of life in women with breast cancer
- Improved clinical outcomes associated with statin use during adjuvant chemotherapy
- Risk of CNS relapse following adjuvant trastuzumab therapy
- Upcoming Abstracts for Her2 Breast Cancer ASCO 2014
- Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 test
- Comorbidity, metastases, and survival in women with metastatic breast cancer (mBC) re
- Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 pepti
- Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-
- Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu
- Primary analysis of the prospective, randomized, single-blinded phase II trial of AE3
- Profiling of signaling pathways in live tumor cells to assess drug mechanism of actio
- Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the
- Regulation of C-terminal and N-terminal fragments of HER2 by mRNA.
- Adjuvant trastuzumab in the treatment of small HER2-positive tumors: A single institu
- Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic trea
- An immune-related signature for prediction of risk of late recurrences beyond prolife
- Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance t
- Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurre
- Association between the expression of hormone receptors and HER2/Neu in early breast
- Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal
- Breast cancer subtypes according to body mass index and insulin resistance.
- AE37 vaccine
- oral bisphosphonate treatment on bone mineral density in osteopenic women receiving a
- Hey! Cost Effectiveness for our Canadian friends . . .
- Adjuvant palbociclib (P) plus endocrine therapy (ET)
- Breast cancer in young women age 35 and under: Patterns of care and outcome.
- Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therap
- Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years
- Clinical impact of differential risk stratification by breast cancer index (BCI) vers
- We've come a long way, Baby!
- What's Hot at the ASCO Annual Meeting This Year?
- Breast Cancer Preview: Critical Issues Resolved?
- New ASCO Guidelines Address HER2-Positive Breast Cancer
- SABCS 2014 All Abstracts
- ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 2
- ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 1
- SABCS 2016 individual abstracts
- SABCS 2017 abstracts
- SABCS 2018 abstracts available now.
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab
- Access 2019 ASCO Annual Meeting Proceedings – Breast Cancer Abstracts
- 2019 SABCS Abstracts
- 2020 SABCS abstracts
- 2020 ASCO abstracts
- Another new seems promising treatment
- ARX788: A potential new treatment after T-DM1, Enhertu.
- 2021 ASCO abstracts.
- Top 5 Studies in Breast Cancer from ASCO 2021
- 2021 SABCS Abstracts
- 2022 ASCO abstracts
- 2022 SABCS Abstracts
- 2023 ASCO abstracts.
- 2023 SABCS abstracts
- 2024 Miami Breast Cancer Conference Abstracts